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 Chapter 30 
 Protective Effects of PACAP in the Retina 
 Tamas  Atlasz ,  Alexandra  Vaczy ,  Dora  Werling ,  Peter  Kiss ,  Andrea  Tamas , 
 Krisztina  Kovacs ,  Eszter  Fabian ,  Timea  Kvarik ,  Barbara  Mammel , 
 Bese  Danyadi ,  Emese  Lokos , and  Dora  Reglodi 
 Abstract  Pituitary adenylate cyclase activating polypeptide (PACAP) is a widespread 
neuropeptide that is well known for its general cytoprotective effects in different neu-
ronal injuries, such as traumatic brain and spinal cord injury, models of neurodegenera-
tive diseases, and cerebral ischemia. PACAP and its receptors also occur in the retina. 
In this review, we summarize the retinoprotective effects of PACAP. In vitro, PACAP 
is protective against glutamate, thapsigargin, anisomycin, oxidative stress, UV light, 
high glucose, inﬂ ammation, and anoxia. Both the neural retina and the pigment epithe-
lial cells can be protected by PACAP in various experimental paradigms. In vivo, the 
protective effects of intravitreal PACAP treatment have been shown in the following 
models in rats and mice: excitotoxic injury induced by glutamate,  N -methyl- D -aspartate 
(NMDA) or kainate, ischemic injury induced by carotid artery ligation and high intra-
ocular pressure, degeneration caused by UV-A light, optic nerve transection, and strep-
tozotocin-induced diabetic retinopathy as well as retinopathy of prematurity. Molecular 
biological methods have revealed that PACAP activates anti-apoptotic, while inhibits 
pro-apoptotic signaling pathways, and it also stimulates an anti-inﬂ ammatory environ-
ment in the retina. Altogether, PACAP is suggested to be a potential therapeutic retino-
protective agent in various retinal diseases. 
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 Abbreviations 
 6-OHDA  6-hydroxydopamine 
 AIF  Apoptosis inducing factor 
 AMPA receptor  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor 
 Bad  Bcl-2-associated death promoter 
 Bax  Bcl-2-associated X protein 
 BBB  Blood–brain barrier 
 BCCAO  Bilateral common carotid artery occlusion 
 Bcl-2  B-cell lymphoma 2 
 Bcl-xl  B-cell lymphoma-extra large 
 cAMP/PKA/CREB  Cyclic AMP/protein-kinase A/cAMP response element- 
binding protein 
 CIAP-1  Cellular inhibitor of apoptosis protein-1 
 CINC  Cytokine-induced neutrophil chemoattractant 
 CNS  Central nervous system 
 CNTF  Ciliary neurotrophic factor 
 CtBP2  C-terminal binding protein 2 
 DR  Diabetic retinopathy 
 eNOS  Endothelial nitric oxide synthase 
 ERG  Electroretinography 
 ERK  Extracellular signal-regulated kinase 
 Fas TNFR  Fas tumor necrosis factor receptor 
 FITC  Fluorescein isothiocyanate 
 GCL  Ganglion cell layer 
 GFAP  Glial ﬁ brillary acidic protein 
 HIF1α, 2α, 3α  Hypoxia-inducible factor 1-alpha, 2-alpha, 3-alpha 
 HO-1  Heme oxygenase-1 
 HSP-27  Heat shock protein-27 
 IL-1β  Interleukin-1 beta 
 INL  Inner nuclear layer 
 IP3  Inositol trisphosphate 
 IPL  Inner plexiform layer 
 JNK  c-Jun N-terminal kinase 
 LPS  Lipopolysaccharide 
 MAPK  Mitogen-activated protein kinase 
 MIP-1  Macrophage inﬂ ammatory protein 1 
 MSG  Monosodium glutamate 
 NBL  Neuroblast layer 
 NF-kB  Nuclear factor-kB 
 NFL  Nerve ﬁ ber layer 
 NMDA  N -methyl- D -aspartate 
 NPY  Neuropeptide Y 
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 OLM-ILM  Outer limiting membrane-inner limiting membrane 
 ONL  Outer nuclear layer 
 OPL  Outer plexiform layer 
 Ops  Oscillatory potentials 
 PAC1  PACAP receptor 1 
 PACAP  Pituitary adenylate cyclase activating polypeptide 
 PACAP KO  PACAP knockout 
 PKCα  Protein kinase C alpha 
 PLC gamma-1  Phospholipase C gamma-1 
 RANTES  Regulated on activation normal T cell expressed and secreted 
 RGCs  Retinal ganglion cells 
 ROP  Retinopathy of prematurity 
 ROS  Reactive oxygen species 
 RPE  Retinal pigment epithelial 
 RSK1/2  Ribosomal s6 kinase 1, 2 
 sICAM  Soluble intercellular adhesion molecule 
 STAT4  Signal transducer and activator of transcription 4 
 TGF-β  Transforming growth factor beta 
 TH  Tyrosine hydroxylase 
 TIMP-1  Tissue inhibitor metallopeptidase inhibitor-1 
 Trail R2 DR5  TRAIL receptor 2—death receptor 5 
 TUNEL  Terminal deoxynucleotidyl transferase dUTP nick end 
labeling 
 UV-A, B  Ultraviolet A, ultraviolet B 
 VEGF  Vascular endothelial growth factor 
 VGAT  Vesicular GABA transporter 
 VGLUT1  Vesicular glutamate transporter 1 
 VIP  Vasoactive intestinal peptide 
 VPAC1  Vasoactive intestinal peptide (VIP) receptor type 1 
 VPAC2  Vasoactive intestinal peptide (VIP) receptor type 2 
 ZO-1  Zona occludens protein 1 
 Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) 
 Pituitary adenylate cyclase activating polypeptide (PACAP) was isolated from ovine 
hypothalamus based on its stimulating effect on adenylate cyclase enzyme in ante-
rior pituitary cells [ 1 ,  2 ]. PACAP has two isoforms: PACAP1-27 and PACAP1- 38, 
containing 27 and 38 amino acids, respectively. PACAP is a member of the vasoac-
tive intestinal peptide (VIP)/secretin/glucagon superfamily [ 3 ]. Its receptors can be 
divided into two groups, PAC1 receptor and VPAC receptors (VPAC1 and VPAC2) 
[ 4 ]. The biological effects of PACAP are diverse [ 4 ], but one of the most studied 
actions of the peptide is its potent neuroprotective effect. Earlier studies have shown 
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that PACAP protects neurons in vitro against various toxic agents (glutamate, 
6-OHDA, oxidative stress, etc.). The neuroprotective role of PACAP has been also 
demonstrated in vivo in different animal models, such as cerebral ischemia, trau-
matic brain injury, spinal cord injury, and Parkinson’s disease. These neuroprotec-
tive effects have been summarized in several reviews by different authors [ 4 – 11 ]. 
 PACAP is also protective in sensory organs, including the auditory and visual 
systems [ 12 – 14 ]. The retina is a special tissue, an extension of the central nervous 
system (CNS) containing different neurons, and it also provides an excellent model 
to measure neuronal degenerations. PACAP has been shown to protect the different 
neurons of the retina in numerous in vitro and in vivo models of retinal degenera-
tions. The purpose of the present review is to summarize the current knowledge of 
the retinoprotective functions of PACAP. The retinoprotective effects of PACAP 
provide a new, exciting area of research, and several novel data have been published 
since the appearance of the ﬁ rst two extensive reviews on the retinoprotective effects 
of PACAP [ 12 ,  15 ]. Therefore, we brieﬂ y summarize retinoprotective effects until 
2010 and discuss ﬁ ndings in the last 5 years more in detail. 
 Distribution of PACAP in the Retina 
 Several studies have described the presence of PACAP and PACAP receptors in the rat 
retina. PACAP immunopositive cell bodies were found in amacrine, horizontal cells in 
the inner nuclear layer (INL), in the ganglion cell layer (GCL) and also in the Muller 
glial cells. PACAP positive nerve ﬁ bers were also present in the nerve ﬁ ber layer 
(NFL), and also in the inner plexiform layer (IPL), but no PACAP positivity was found 
in the outer nuclear layer (ONL) or the retinal pigment epithelium (RPE) layer [ 16 – 20 ]. 
The presence of PACAP was also found in the mouse [ 21 ], teleost [ 22 ], turtle [ 23 ], and 
chicken retina [ 24 ]. PACAP appearance showed in a subset of retinal ganglion cells, 
which cells are photosensitive due to expression of melanopsin. The PACAP expression 
in this subset of ganglion cells is partly controlled by dopamine, while it is not affected 
by photoreceptor degeneration [ 25 ,  26 ]. Melanopsin-containing retinal ganglion cells 
are known to be more resistant in various types of degeneration, such as axonal injury 
[ 27 ], and it has been proven by numerous studies that these melanopsin-containing 
cells almost all co-store PACAP, which might contribute to the highly resistant nature 
of these cells [ 28 – 30 ]. PACAP- and melanopsin-containing retinal ganglion cells play 
an important role in several light-activated non-image-forming functions of the retina 
and the complimentary signaling due to PACAP neurotransmission has been shown to 
be important in addition to the glutamatergic signaling [ 31 ,  32 ]. 
 PACAP immunopositivity was also found in the limboretinal pathway [ 33 ]. PACAP 
and its receptors were also described in the developing retina of mammals [ 34 ]. In devel-
oping chicken retina PACAP was expressed in the INL from embryonic day 8 (E8) [ 35 ]. 
In zebraﬁ sh during the pharyngula period, at 24 h of post fertilization PACAP-like 
immunoreactivity (PACAP-LI) was detected in the superﬁ cial layer of the retina, and 
during the hatching period, at 72 h of post fertilization in the GCL [ 36 ]. PACAP-LI was 
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absent from the retina in the zebraﬁ sh at day 13 of larval development, suggesting that 
PACAP may have a role in the control of cell differentiation and proliferation [ 36 ,  37 ]. 
In the rat, PACAP mRNA was expressed in the GCL in the developing retina at E20 [ 38 ]. 
 Distribution of PACAP Receptors in the Retina 
 Earlier studies showed the distribution and localization of PACAP receptors in the 
retina. Nilsson et al. [ 39 ] characterized the receptors of PACAP and their coupling 
to adenylate cyclase in albino rat eye, and D’Agata and Cavallaro also described the 
expression of PACAP/VIP receptor variants and their coupling to phospholipase C 
in the rat retina [ 16 ]. In chicken retina at early stage (E6) PAC1 receptor and its 
mRNA can be found [ 35 ]. The mRNA of PACAP receptors and the protein expres-
sion have also been shown in all the layers of the neonatal rat retina [ 40 ]. Seki and 
coworkers described the localization and strong expression of PAC1 receptor and its 
mRNA in different retinal layers (NFL, INL, GCL), weaker expression in the ONL, 
OPL, IPL, and the outer segments of the photoreceptors in the rat retina [ 41 ,  42 ]. 
Moreover, different PAC1 receptor mRNA variants (short, hop) were found in the 
cell bodies and the processes of ganglion and amacrine cells [ 41 ]. Finally, PAC1 
receptor has been described in Muller glial cells [ 19 ,  43 ]. 
 PACAP also plays a role in retinal development. The expression of the speciﬁ c 
PAC1 receptor and VPAC receptors has been conﬁ rmed in the developing mamma-
lian retina, including the retinal progenitor cells [ 44 ]. A shift in PAC1 receptor iso-
form expression (null, hip, hop1, hiphop1) during development might explain the 
different roles exerted during differentiation of retinal neural elements [ 45 ,  46 ]. 
 PACAP controls the proliferation of retinal progenitor cells through the activa-
tion of all 3 receptors, and the cAMP/PKA/CREB pathway. This activation resulted 
in downregulation of cyclin D1 and the transcription factor Klf4, while p27 kip1 pro-
tein content did not change [ 44 ,  47 ]. The overall effect of these changes was an 
antiproliferative effect. 
 Protective Effects of PACAP in the Retina In Vitro 
 The in vitro protective effects are summarized in Table  30.1 .
 In Vitro Protective Effects in the Neural Retina 
 The ﬁ rst in vitro studies presented that VIP, a related peptide to PACAP [ 48 ], or 
PACAP1-27 and PACAP1-38 [ 49 ] have retinoprotective effect against glutamate 
toxicity using cultured retinal neurons. PACAP1-27, PACAP1-38, and VIP increased 
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 Table 30.1  Summary of the effects of PACAP in the retina in vitro 
 Cell type  Treatments  Observed effect  Reference 
 Retinal cells from 
pups 
 Glutamate-induced 
toxicity, in vitro 
PACAP1-27 and 
PACAP1-38 (10, 
100 nmol–1 μmol, 
dose dependent), 
cultured 
 ↑: Intracellular Ca 2+ and no 
effect by PACAP1-27, 
PACAP1-38 
 ↑: cAMP by VIP 
 ↑: MAPK and cAMP by 
PACAPs, antagonized by 
PACAP6-38 (PACAP antagonist) 
and H-89 (PKA inhibitor) 
 [ 49 ] 
 Retinal explants 
from newborn 
 Cell death by 
anisomycin (1 μg/ml) 
within the neuroblastic 
layer (NBL) 
 1–10 nM PACAP1-38 
 ↓: TUNEL positive and pyknotic 
cells by PACAP1-38, 
PACAP1- 27, or maxadilan 
(PAC1 receptor agonist), blocked 
by PACAP6-38 or Maxd.4 
(PAC1 receptor antagonist) 
 ↑: pCREB by PACAP1-38; 
cAMP but not IP3 by PACAP, 
pyknotic proﬁ les blocked by 
Rp-CAMPS (PKA inhibitor) 
 [ 40 ] 
 Photoreceptor cells  Cell death by 
thapsigargin (10 nmol 
PACAP1-38) 
 ↓: Dead cells  [ 40 ] 
 Turtle horizontal 
cells 
 Anoxic condition 
(PACAP1-38, 0.165 
μmol) 
 ↑: Light response time dependent  [ 50 ] 
 Developing retinal 
explant 
 PACAP1-38, 10 nmol  ↑: cAMP, p-CREB, nuclear Klf4 
 ↓: cyclin D1 
 No change in p27  kip1 
 [ 44 ,  47 ] 
 RGC-5 retinal 
ganglion cells 
 PACAP1-5 
(1–100 nmol); 
UV-B-induced injury 
 ↑: Viability, bcl-2 
 ↓: Bax 
 [ 73 ] 
 RGC-5 retinal 
ganglion cells 
 Cyclic PACAP1-5 
(1–100 μmol), 
UV-B-induced injury 
 ↑: Viability, bcl-2 
 Maintained structural integrity 
 ↓: Apoptosis, ROS, bax, caspase-3 
 [ 73 ,  91 ] 
 ARPE19, human  PACAP1-38 
0.1–1 μmol 
 (IL-1β stimulation) 
 ↓: The IL-1beta stimulated IL-6, 
IL-8, and MCP-1 mRNA and 
protein l, NF-kB 
 [ 51 ] 
 ARPE19, human  Oxidative stress by 
H 2 O 2 
 (PACAP1-38: 
10 pmol–1 μmol) 
 ↑: Viable cells, blocked by 
PACAP6-38 and reduced by 
PI3K/Akt inhibitor but not 
MAPK inhibitors 
 ↓: Apoptosis 
 [ 52 ] 
 ARPE19, human  Oxidative stress by 
 H 2 O 2 
 PACAP1-38 
10–100 nM 
 ↑: pERK/CREB; Akt; Lyn; Yes; 
Src; 
 ↓: p-p38; p-JNK;Bad; Bax; Trail 
R2 DR5; FADD; Fas TNFR; 
HIF1-alpha; HO-1; cIAP-1; 
HSP-27; SMAC/Diablo; p53; 
eNOS, Paxillin, PLCgamma-1, 
STAT4, RSK1/2 
 [ 53 ] 
(continued)
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cAMP, and the protective effects of VIP or PACAP isoforms were antagonized by 
VIP6-28 (VIP antagonist) or PACAP6-38 (PACAP antagonist), respectively. In 
addition, H-89 (PKA inhibitor) also decreased the protective effects of VIP or 
PACAP1-27, PACAP1-38. 
 Silveira et al. [ 40 ] found that anisomycin (1 μg/ml) inhibited protein synthesis 
and induced cell death in the neuroblastic layer of retinal explants from newborn 
rats. PACAP1-27 or PACAP1-38 dose-dependently prevented the anisomycin-
induced cell death. One nanomolar PACAP1-27 or PACAP1-38 administration in 
parallel signiﬁ cantly reduced the number of dead cells with the terminal deoxynu-
cleotidyl transferase dUTP nick end labeling (TUNEL) procedure and the number 
of pyknotic proﬁ les per mm 2 in the neuroblast layer (NBL). A similar retinoprotec-
tive effect was observed with PAC1 receptor agonist maxadilan, but not with gluca-
gon. Neuroprotection by PACAP1-38 was also measured in photoreceptor cell 
death caused by thapsigargin in the ONL [ 40 ]. In the retinal explant model, 
PACAP6-38 and the speciﬁ c PAC1 receptor antagonist Maxd.4 antagonized the 
neuroprotective effect. Molecular and immunohistochemical analysis demonstrated 
that the retinoprotective effects are most probably mediated by the PAC1 receptor, 
which is expressed in all the retinal layers of the neonatal retina. Treatment of 
PACAP1-38 induced CREB immunoreactivity in the NBL. PACAP1-38 adminis-
tration also increased cAMP, but not IP3, and a cAMP-dependent protein kinase 
inhibitor Rp-cAMPS could block the retinoprotective effects of PACAP1-38. 
 In adult turtles, horizontal cells showed light responses 18, 22, 42, and 46 h after 
removal of the eyes. Rabl et al. [ 50 ] demonstrated that the amplitudes of light 
responses were larger in slices at all time-points in PACAP1-38-containing solution 
(0.165 μM PACAP) compared to control retinal slices in anoxic condition. These 
results provide evidence that PACAP1-38 has neuroprotective effects in hypoxic/
anoxic conditions in the adult turtle retina in vitro. 
Table 30.1 (continued)
 Cell type  Treatments  Observed effect  Reference 
 ARPE19, human  Normal and high 
glucose and Il-β1, + 
100 nmol PACAP1-38 
or VIP 
 ↑: Transendothelial resistance, 
claudin and Zo-1 tight junctional 
protein expression 
 ↓: Blood–retinal barrier 
permeability 
 [ 55 ] 
 ARPE19, human  PACAP1-38 1 and 
10 μmol 
 PACAP6-38 1 and 
10 μmol 
 ↑: Semaphorin4a mRNA, protein 
 ↑: pERK 
 PACAP6-38 blocked these 
effects and ↑: IL-6 
 [ 54 ] 
 Retinoblastoma Y79 
cells, human 
 PACAP1-38 and 
PACAP6-38 nmol and 
1–5 μmol 
 Nanomolar: no effect on cell 
viability 
 Micromolar: 
 ↓: Cell viability, further ↓: with 
PACAP6-38; no effect: 
PACAP1-27 and maxadilan 
 [ 115 ] 
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 In Vitro Protective Effects in the Retinal Pigment 
Epithelial Cells 
 Retinal pigment epithelial (RPE) cells play an essential role in photoreceptor sur-
vival and metabolism. Several diseases are associated with malfunction of the pig-
ment cells. The ﬁ rst results concerning the effects of PACAP came from Zhang 
et al. [ 51 ]. Presence of mRNA for PAC1 and VPAC1 receptors was conﬁ rmed in 
unstimulated human RPE cells (ARPE19). VPAC2 mRNA was expressed in cells 
stimulated with IL-1β. PACAP treatment at 0.1–1 μM concentrations inhibited the 
IL-1 β-stimulated IL-6, IL-8, and MCP-1 mRNA and protein levels. The dense 
immunoﬂ uorescence of NF-kB in the nucleus after stimulation with IL-1β was 
decreased by PACAP [ 51 ]. Studies following these ﬁ rst results in pigment cells 
revealed several other effects of PACAP in these retinal cells. 
 ARPE19 cells exposed to PACAP1-38 could be rescued against oxidative stress 
induced by H 2 O 2 in a dose-dependent manner [ 52 ]. Highest efﬁ cacy was observed 
at 100 nM PACAP concentration, but it was effective in a range 10 pM–1 μM, while 
not effective at 1 pM. Using ﬂ ow cytometric and JC-1 assay, PACAP treatment was 
proven to reduce apoptotic cell death. PACAP1-38 and 6-38 alone had no effect on 
cell survival. The survival-promoting effect was inhibited by PI3K/Akt inhibitors, 
but not affected by MAPK inhibitors [ 52 ]. A subsequent study investigated the sig-
naling pathways in oxidative stress-induced pigment epithelial cell damage [ 53 ]. 
Western blot results revealed that PACAP treatment could activate the protective 
ERK/CREB and Akt pathways, while it inhibited the phosphorylation of p38 MAPK 
and JNK. Several cytokines and other apoptotic markers were altered upon oxida-
tive stress, as measured by cytokine and phospho-kinase arrays. PACAP administra-
tion counteracted several of these changes. 10 and 100 nM PACAP decreased the 
oxidative stress-induced increases of the proinﬂ ammatory and/or proapoptotic fac-
tors Bad; Bax; Trail R2 DR5; FADD; Fas TNFR; HIF-1α; HO-1; cIAP-1; HSP-27; 
SMAC/Diablo; p53; eNOS; Paxillin; PLCgamma-1; STAT4; RSK1/2. In contrast, 
PACAP could increase the protective Lyn; Yes; and Src. 
 A more recent study has reported that PACAP regulates semaphorin4A expres-
sion from RPE cells [ 54 ]. The semaphorin protein family has members that inﬂ u-
ence brain and retinal development, by providing neural guidance. Semaphorin4A 
is expressed in the GCL, INL and RPE cell during the developmental period of 
contact-building between photoreceptors and RPE cells. Human ARPE cells were 
cocultured with PC12 cells (prototype neuronal cells) based on a collagen vitrigel 
membrane. The authors found that in the presence of neural cells the protein and 
mRNA levels of semaphorin4A (but not other semaphorins) were increased, an 
effect mimicked by PACAP (but not VIP, NPY, or enkephalin). Furthermore, this 
effect was also associated with ERK phosphorylation (but not that of JNK or p38 
MAPK). All these effects of PACAP were blocked by the PACAP antagonist 
PACAP6-38. Furthermore, PACAP6-38 downregulated the cytokine IL-6 expres-
sion, indicating that endogenous PACAP participates in the neural cell-induced IL-6 
production (other cytokines out of the tested ones were not inﬂ uenced by the 
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 neuronal co-culture). These results suggest that the PACAP secreted by neural cells 
regulates several factors secreted by RPE cells, important for retinal development 
and homeostasis [ 54 ]. The local secretion of PACAP necessary for these effects is 
supported by the high concentration used in this study (1 μM and 10 μM PACAP, 
lower concentrations were not reported), a concentration much higher than the ones 
reported to exert protective effects against oxidative stress [ 52 ,  53 ]. 
 Another study investigated the potential of PACAP and VIP against the disrup-
tion of tight junctions in the retina, a major factor in macular edema developing in 
diabetic retinopathy [ 55 ]. ARPE19 cells were cultured either in normal glucose or 
in high glucose in combination with the pro-inﬂ ammatory IL-1β. Effects on perme-
ability were evaluated by measuring both apical-to-basolateral movements of ﬂ uo-
rescein isothiocyanate (FITC) dextran and transepithelial electrical resistance [ 55 ]. 
Results of these experiments demonstrated that normal glucose + IL-1β and, to a 
greater extent, high glucose + IL-1β signiﬁ cantly increased FITC-dextran diffusion, 
paralleled by decreased electrical resistance. PACAP or VIP reversed these effects. 
Furthermore, high glucose + IL-1β-induced reduction of claudin-1 and ZO-1 expres-
sion was reversed by PACAP and VIP. Occludin expression was not affected in any 
of the conditions tested. Altogether, these ﬁ ndings show that both peptides counter-
act high glucose + IL-1β-induced damage in ARPE19 cells, suggesting that they 
might be relevant to the maintenance of outer blood–retinal barrier function in 
edema accompanying diabetic retinopathy [ 55 ]. These results are in accordance 
with our earlier observations in an in vitro blood–brain barrier (BBB) model [ 56 ]. 
We found that PACAP treatment improved the barrier properties of the brain endo-
thelium. PACAP induced an increase in the transendothelial electrical resistance, 
which is the most important marker of the tightness of the tight junctions. Moreover, 
PACAP had a protective role against glucose deprivation- and oxidative stress- 
induced junctional damage in microvascular brain endothelial cells [ 56 ]. 
 Protective Effects of PACAP in the Retina In Vivo 
 The in vivo protective effects are summarized in Table  30.2 .
 Excitotoxic Injury in the Retina 
 Glutamate, a nonessential amino acid, acts as an excitatory neurotransmitter in the 
retina under normal conditions. However, glutamate in high concentrations can be 
toxic to the retinal cells by overstimulation of the glutamate receptors. Monosodium 
glutamate (MSG) administration given systemically passes the BBB of newborn 
rats and so it can, can injure the retina [ 57 ] and lead to loss of the entire inner retinal 
layers [ 58 ]. The excitotoxic damage of the retina is a main factor in retinal diseases, 
such as glaucoma and ischemia-induced retinopathy. We have previously shown in 
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a number of studies that PACAP is protective against excitotoxicity induced by 
systemic monosodium-glutamate lesion. We showed that, three times intravitreal 
MSG treatment on postnatal days 1, 5 and 9 caused severe neurodegeneration in the 
inner retinal layers in newborn rat pups [ 58 ,  59 ]. Three weeks after the MSG admin-
istration the thickness of the total retina was decreased, the distance of the outer 
limiting membrane-inner limiting membrane (OLM-ILM) was only half of the nor-
mal retina. In addition, the IPL almost disappeared, and the fusion of the INL and 
GCL could be observed. The number of the cells per 100 μm in the GCL was also 
decreased [ 58 – 61 ]. Although PACAP1-38 is able to cross the BBB, systemic 
PACAP1-38 treatment caused insigniﬁ cant improvement of the retinal morphology 
following MSG-induced excitotoxic injury [ 62 ]. In contrast, intravitreally injected 
PACAP1-38 (1–100 pmol) resulted in signiﬁ cant amelioration of this degeneration 
[ 58 ,  59 ,  61 ]. While 1 pmol PACAP1-38 was slightly effective, treatment with 
100 pmol PACAP1-38 was able to signiﬁ cantly attenuate the MSG-induced toxicity 
and the entire retina seemed to be normal. Similar protection could be seen by 
PACAP1-27 treatment [ 60 ]. The application of the two widely used PACAP antago-
nists (PACAP6-38, PACAP6-27) led to a more pronounced degeneration, indicating 
that, endogenously present PACAP plays a key role against retinal toxicity [ 60 ]. A 
similar degree of retinoprotection was found using enriched environment, but com-
bining these two neuroprotective strategies (PACAP and enriched environment) did 
not result in increased neuroprotection in excitotoxic retinal injury [ 63 ]. 
 Cell-type speciﬁ c effects of PACAP were shown in MSG-induced retinal degenera-
tion by means of immunohistochemistry. In the MSG-treated retinas, the cell bodies 
and processes in the INL, IPL, and GCL layers displayed less immunoreactivity for 
vesicular glutamate transporter 1 (VGLUT1), tyrosine hydroxylase (TH), vesicular 
GABA transporter (VGAT), parvalbumin, and calretinin. After MSG treatment the 
calbindin-positive horizontal cells did not appear to be affected. In MSG + PACAP1-38 
co-treated retinas, the immunoreactivity patterns were similar compared to the normal 
eyes. These data suggest that PACAP has a general, but not subtype-speciﬁ c protective 
mechanism against glutamate-induced excitotoxic injury in the rat retina [ 64 ]. 
 We also studied potential protective signaling mechanisms in MSG treated reti-
nas. We found that intravitreal administration of PACAP preceding the MSG treat-
ments induced signiﬁ cant increases in the phosphorylation, that is, the activation of 
ERK1/2 and its downstream target, CREB, 12 h after the treatment compared to the 
contralateral untreated eye during the ﬁ rst two treatments, with no further eleva-
tions 24 h after treatments. These results demonstrate that the degenerative effect of 
MSG and the protective effect of PACAP involve complex kinase signaling path-
ways and are related to cAMP/ERK/CREB activation [ 65 ]. Furthermore, after MSG 
treatment proapoptotic signaling proteins such as caspase-3, JNK, apoptosis induc-
ing factor (AIF) and cytochrome-c increased, and some anti-apoptotic proteins 
(phospho- PKA, phospho-Bad, Bcl-xL, 14-3-3) decreased. Co-treatment with 
PACAP1-38 counteracted the MSG-induced apoptotic effects, the level of pro-
apoptotic signals was signiﬁ cantly decreased, while the anti-apoptotic proteins were 
signiﬁ cantly increased [ 65 – 67 ]. A follow-up study conﬁ rmed the anti-apoptotic 
effect of PACAP in MSG-induced retinal lesion of the newborns by reinforcing that 
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PACAP decreased caspase-3 levels and also demonstrating the decreased level of 
caspase-9 [ 68 ]. In addition, we showed that the PACAP antagonist PACAP6-38 
increased cytochrome-c release, caspase-3, JNK activity and decreased phospho-
Bad, phospho PKA, Bcl-xL, 14-3-3 protein activity [ 66 ,  67 ]. These in vivo observa-
tions, similarly to the results of Atlasz et al. [ 60 ], indicating that endogenously 
present PACAP has retinoprotective effects in glutamate-induced excitotoxicity. 
 We studied the short-term functional consequences of MSG treatment in the 
mouse retina. Spontaneous and light-evoked spikes of retinal ganglion cells (RGCs) 
from wild type mice were recorded using a 60-channel multielectrode array. MSG 
remarkably elevated the free intracellular calcium (Ca 2+ ) concentration and also 
increased the spontaneous spiking 4–5 min after drug application. During this time, 
spike correlations between RGC pairs were reduced. However, after 10–15 min of 
MSG application, the spontaneous activity of most RGCs was dramatically reduced 
or totally eliminated. Pretreatment with PACAP1-38 prevented the MSG effects as 
indicated by little or no change in the spontaneous spiking patterns during the course 
of recordings (up to 60 min). Moreover, the Ca 2+ inﬂ ux was noticeably decreased by 
PACAP1-38. In addition, MSG blocked the light-evoked responses of all recorded 
cells. Based on these data, application of PACAP1-38, rescued RGCs from the 
short-term MSG-induced insults [ 69 ]. 
 Kainic acid is a glutamate receptor agonist, which leads to excitotoxic cell death 
in the CNS, including the retina [ 43 ]. It was found that 5 nmol kainic acid caused an 
extensive loss of AMPA/kainate receptors expressing ganglion cells [ 70 ]. Previously 
we showed that microiontophoretically applied PACAP1-38 could block the excit-
atory effects of kainic acid in several brain areas in vivo [ 71 ]. In the rat retina, 
pretreatment with 10 pmol intravitreal PACAP1-38 was neuroprotective against 
kainic-acid induced neurotoxicity, as shown by the attenuated ganglion cell loss [ 43 ]. 
 N -methyl- D -aspartate (NMDA) treatment also leads to similar lesions. A radio-
immunoassay analysis showed that in contrast to VIP, retinal PACAP levels do not 
change after intravitreal NMDA injection, which might be caused by a compensa-
tory upregulation [ 72 ]. A recent study has conﬁ rmed that PACAP-mediated path-
ways are protective in NMDA-induced retinal lesion. Cheng et al. [ 73 ] showed that 
intravitreal NMDA injection led to a decrease in light aversion, and decreases in the 
a and b-waves in the electroretinogram accompanied by a photopic negative 
response. These alterations were reversed by cyclic PACAP1-5 treatment. This 
treatment also resulted in decreased ganglion cell loss and apoptosis assessed by 
TUNEL-staining [ 73 ]. 
 A similar protective effect was described in mice with PACAP1-38, at a concen-
tration of 100 pmol. The PACAP-attenuated NMDA-induced retinal damage in 
mice was associated with modulation of the microglia/macrophage status into an 
acquired deactivation subtype [ 74 ]. NMDA injection led to an increase in microglia/
macrophage number, while PACAP co-administration attenuated this effect in addition 
to the diminished ganglion cell loss. The co-injection of the antagonist PACAP6-38 
counteracted these protective effects and the beneﬁ cial effects were not observed in 
IL-10 knockout mice. PACAP administration also led to elevated expression of the 
mRNA for the protective cytokines IL-10 and TGF-β [ 74 ]. In summary, these results 
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show that acquired deactivation type of the microglia/macrophage cells favors 
neuroprotection in the retina and this is stimulated by PACAP. 
 The question was raised whether these apparent morphological improvements by 
PACAP administration also lead to functional amelioration in MSG-induced retinal 
damage [ 75 ]. Electroretinographic recordings revealed a marked decrease in both 
the b- and a-wave values after MSG treatment, reﬂ ecting the function of the inner 
retinal layers and the photoreceptors, respectively. In retinas receiving intravitreal 
PACAP treatment, these values were signiﬁ cantly increased. Thus, the functional 
outcome, although not parallel with the morphology, was signiﬁ cantly improved 
after PACAP treatment. These observations are important from the clinical point of 
view, showing, that PACAP treatment is able to improve the functional properties of 
the retina in excitotoxic damage [ 75 ]. 
 Ischemic Injury in the Retina 
 Retina is one of the most sensitive tissues to hypoxia in the human body. Several 
diseases such as artery occlusion, diabetic retinopathy and high intraocular pressure 
cause hypoperfusion in the retina. Depending on the rat strain, permanent bilateral 
common carotid artery occlusion (BCCAO) leads to reduction in the cerebral blood 
ﬂ ow, causes hypoperfusion-induced biochemical and behavioral changing and also 
produces retinal degeneration [ 76 ,  77 ]. Our research group showed in a series of 
experiments that intravitreal PACAP is highly protective in ischemic retinal lesion. 
We found that BCCAO caused severe damage in all layers of the retina. Two weeks 
after permanent carotid artery ligation, the thickness of the plexiform layers was 
markedly decreased, and as a consequence, the distance between the OLM-ILM 
was signiﬁ cantly less compared to the control retina. In several treated animals, in 
the IPL some dots of about 1 μm in diameter were seen. Based on the relatively even 
distribution, these dots seemed to be degenerating bipolar cell terminals. In addi-
tion, the outer segments of the photoreceptors became shorter, and their structure 
was also damaged after the insult [ 76 ]. Intravitreal PACAP1-38 treatment following 
BCCAO led to a nearly intact appearance of the retinal layers, which is well reﬂ ected 
by the morphometric analysis. The thickness of all retinal layers, but not the number 
of cells in the GCL, was preserved in PACAP1-38 treated animals. PACAP antago-
nist PACAP6-38 signiﬁ cantly attenuated the protective effects of PACAP1-38. 
 In 2010, we provided immunohistochemical description of several retinal cell 
types that were damaged by BCCAO and could be partially or fully rescued by 
intravitreal PACAP1-38 treatment. Using the cell type speciﬁ c markers (VGLUT1, 
TH, VGAT, parvalbumin, calbindin, calretinin, PKCα, and GFAP) marked changes 
were detected after BCCAO, and the alterations observed in the immunostaining for 
all examined antisera were counteracted by intravitreal PACAP1-38 treatment [ 13 ]. 
These studies provided the basis for the promising therapeutic potential of PACAP 
in ischemic retinal diseases [ 78 ]. 
 Subsequent studies conﬁ rmed these original observations. Seki et al. [ 79 ] showed 
that intravitreal PACAP treatment protected ganglion cells against a different kind 
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of ischemic lesion induced by high intraocular pressure. In this model, PACAP 
exerted a bimodal protective effect with peaks at 10 fM and 10–100 pM. The protec-
tive effect was blocked by cAMP antagonist at both high and low protective doses, 
while a MAP kinase inhibitor only blocked the effects of PACAP at a low dose, 
suggesting that the protective effects of PACAP are mediated by different signaling 
at low and high doses [ 79 ]. 
 In a series of studies, we conﬁ rmed these ﬁ ndings and compared the efﬁ cacy of 
several analogs and related peptides to PACAP1-38 [ 80 ,  81 ]. We investigated the 
effects of the following PACAP fragments: PACAP 4-13, 4-22, 6-10, 6-15, 11-15, 
and 20-31 and three related peptides (VIP, secretin, glucagon) in BCCAO-induced 
ischemic retinopathy. We conﬁ rmed that the most effective molecule is PACAP1-38, 
while the other fragments or related peptides did not lead to retinoprotection [ 81 ]. 
The only exception was VIP, which showed retinoprotection in a dose ten times 
higher than that of PACAP [ 80 ]. In addition, our preliminary results demonstrate 
that even in form of eye-drops, PACAP can lead to retinoprotective effects in isch-
emic retinopathy, a route of application with major possible clinical relevance [ 82 ]. 
 In order to elucidate some of the molecular mechanisms, we studied MAP 
kinases and Akt expression as well as cytokines in BCCAO-induced retinal isch-
emia in rats [ 83 ]. We revealed that PACAP treatment alone did not inﬂ uence the 
phosphorylation of Akt or the MAPKs, but decreased the hypoperfusion-induced 
activation of both p38MAPK and JNK and increased the activation of the protective 
Akt and ERK1/2 in hypoperfused retinas. The cytokine proﬁ le dramatically changed 
after BCCAO, with most cytokines and chemokines (such as CINC, CNTF, fractal-
kine, sICAM, IL-1, LIX, Selectin, MIP-1, RANTES, and TIMP-1) increased, a 
result attenuated by PACAP. In addition, PACAP increased the expression of vascu-
lar endothelial growth factor (VEGF) and thymus chemokine. These results pro-
vided further insight into the neuroprotective mechanism induced by PACAP in 
ischemic retinal injuries, showing that PACAP ameliorated hypoperfusion injury 
involving Akt, MAPK pathways and anti-inﬂ ammatory actions [ 83 ]. 
 Whether the morphological amelioration is accompanied by functional improve-
ment was tested using electroretinography (ERG) in another set of experiments 
[ 84 ]. Retinal damage and protective effects of PACAP were quantiﬁ ed by the 
changes in the waveforms and amplitudes. BCCAO-induced functional retinal 
degeneration was already observed on postoperative days 2 and lasted throughout 
the entire observation period. Intravitreal injection of PACAP immediately after 
BCCAO resulted in a more retained retinal function as assessed by average ERG 
waveforms compared to the BCCAO-operated groups on both postoperative 2nd 
and 14th days. ERGs of PACAP-treated ischemic eyes were similar to the intact 
controls in contrast to the ERGs of saline-treated BCCAO retinas. PACAP treatment 
signiﬁ cantly counteracted the ischemia-induced alterations in the amplitudes of 
both the “a” and “b” waves of the ERG on postoperative day 14. The elapse time of 
the major oscillatory potentials (OPs) was reduced in the BCCAO-ischemic group, 
but PACAP treatment led to signiﬁ cant protection. The results conﬁ rm that the pre-
viously described morphological protection induced by PACAP treatment is 
reﬂ ected in functional improvement in ischemic retinal lesions [ 84 ]. 
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 A recent study has revealed several metabolomics changes induced by PACAP in 
ex vivo retinal ischemia induced by sodium azide treatment for various periods of 
time [ 85 ]. PACAP induced several changes in addition to the reduction of ischemia- 
induced cell death, VEGF overexpression, and glutamate release. Apoptosis, as 
evaluated by TUNEL staining, was reduced in the ONL, INL, and GCL. Elevated 
levels of caspase-3 mRNA were also reversed by PACAP treatment. Glutamine, a 
precursor of glutamate, was signiﬁ cantly elevated in ischemic conditions, and 
reversed by PACAP administration. Ischemia is associated with oxidative injury and 
so the authors evaluated the oxidative status of the retinal explants. It was found that 
PACAP had a positive effect on glutathione while it reduced the oxidized glutathi-
one levels, and counteracted the increased gamma-glutamyl cysteins levels with 
accompanying increase of cysteine. The accumulation of pro-inﬂ ammatory factors 
and peroxidized lipids was prevented by PACAP. Three nitric oxide metabolites 
were found to be upregulated in ischemic retinas: arginine, ornithine and citrulline. 
Treatment with PACAP reversed these changes. The signiﬁ cantly decreased level of 
cAMP was restored by PACAP treatment and glycolytic ﬂ ues were normalized pre-
venting the over-accumulation of lactate or promoting the downregulation of the 
glyoxalate antioxidant system. Upregulated inositol levels were also abolished. 
PACAP seemed to promote a shift towards pentose-phosphate pathway while main-
taining higher levels of NADPH compared to ischemic controls. It also led to a 
downregulation of purine metabolism. This study concluded that peptidergic sys-
tems, such as PACAP, deserve attention in treating retinal ischemia [ 85 ]. 
 Thanks to all these results, PACAP is now on the list of potential neuroprotective 
molecules in combating ischemic retinopathy [ 78 ,  86 ]. 
 Optic Nerve Injury in the Retina 
 Optic nerve transection is a model of apoptotic neuronal cell death in the adult CNS 
[ 87 ]. Seki et al. [ 88 ] reported that optic nerve trauma resulted approximately 55 % 
loss of cells in the GCL. In this model, the number of cells in the GCL in animals 
treated before the operation with PACAP1-38 at 10 and 100 pmol in 3 μl saline 
(dose-dependent) intravitreally, was signiﬁ cantly increased compared with the con-
trol group on the 14th day after surgery [ 88 ], providing evidence that PACAP is 
protective in this injury model. 
 UV Radiation Injury in the Retina 
 We showed, for the ﬁ rst time, that PACAP protected against two different kinds (dif-
fused and focused) of ultraviolet (UV)-A induced degenerations. Thickness of all lay-
ers as well as the number of cells in the ONL and INL and in the GCL was evaluated 
by standard morphological and morphometrical analyses. After diffuse UV-A 
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irradiation, signiﬁ cant decrease of the number of the cells in the GCL was observed. 
In addition, severe degeneration in the ONL and INL was seen, and the IPL was swol-
len. PACAP1-38 treatment after the UV-A irradiation signiﬁ cantly ameliorated the 
light-induced degeneration, the ONL and INL thickness seemed to be normal, and the 
number of cells in INL, ONL, and GCL was signiﬁ cantly increased [ 89 ]. In a model of 
focused UV-A irradiation, the shape of the laser focus was observed on the retina, tis-
sue gaps were found in the ONL and in the photoreceptor layer, and the IPL was 
reduced. The total thickness of the retina was signiﬁ cantly less than in unaffected areas. 
We observed protective effects of PACAP in all of the different retinal layers [ 90 ]. 
 Succeeding studies conﬁ rmed this effect in several different models. In an 
in vitro model of UV-B irradiation, PACAP was shown to protect RGC-5 retinal 
ganglion cells expressing PAC1 receptors [ 73 ,  91 ]. This effect was mimicked also 
by a cyclic PACAP derivative, cyclic PACAP1-5 [ 73 ]. Furthermore, pretreatment 
with this short derivative effectively blocked apoptosis, maintained structural integ-
rity, and decreased production of reactive oxygen species (ROS). Both PACAP and 
cyclic PACAP1-5 counteracted the UV-B-induced decrease in the protective Bcl-2 
and the increase in the deleterious Bax protein levels [ 73 ]. 
 Diabetic Retinopathy in the Retina 
 Our recent studies have shown that PACAP is also protective in diabetic retinopathy 
(DR), a major microangiopathy affecting the vision of diabetic patients. Our ﬁ rst 
results demonstrated that in the early stages of diabetic retinopathy, amacrine cells 
underwent characteristic degeneration, especially the dopaminergic amacrine cells. 
PACAP prevented the typical alterations induced in 1-month diabetes: the degenera-
tion in arborization and synapses of tyrosine-hydroxylase positive dopaminergic ama-
crine cells [ 13 ]. In a rat model of streptozotocin-induced diabetic retinopathy, early 
signs do not include overall changes in thickness of retinal layers, but the decrease in 
the number of ganglion cells and the upregulation of GFAP as a sign of Müller glial 
cell activation, can be observed. These changes were counteracted by three times 
100 pmol/5 μl intravitreal PACAP administration [ 92 ]. Furthermore, the degeneration 
of the photoreceptor outer segments and terminals was attenuated in PACAP-treated 
rats. PACAP increased the levels of PAC1-receptor and TH determined with molecular 
biological methods. These early results suggested a therapeutic potential in DR. 
 Subsequently, our research group and others conﬁ rmed these early ﬁ ndings [ 93 ]. 
Intraocular PACAP injection markedly attenuated diabetic retinal injury: increased 
levels of the anti-apoptotic p-Akt, p-ERK1, p-ERK2, PKC, Bcl-2, while decreased 
levels of the pro-apoptotic p-p38MAPK and activated caspases (8, 3, 12) were detected. 
The number of apoptotic cells increased in all nuclear layers of diabetic retinas, but 
signiﬁ cantly decreased after PACAP treatment. Our results clearly demonstrated that 
the protective effects of PACAP are mediated, at least partly, by  attenuating apoptosis, 
including also that of the dopaminergic amacrine cells [ 93 ]. Our most recent study 
shed further light on this PACAP-induced retinoprotection. Electron microscopic 
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analysis revealed that retinal pigment epithelium, the ribbon synapses and other syn-
aptic proﬁ les suffered alterations in diabetes. However, in PACAP-treated diabetic 
retinas more bipolar ribbon synapses were found intact in the inner plexiform layer 
than in DR animals. The ribbon synapse was marked with C-terminal binding protein 
2 (CtBP2)/Bassoon and formed horseshoe-shape ribbons, which were more retained 
in PACAP-treated diabetic retinas than in DR rats. These results are supported by 
molecular biological data. The selective degeneration of related structures such as 
bipolar and ganglion cells could be ameliorated by PACAP treatment. In summary, 
intravitreal administration of PACAP may have therapeutic potential in streptozotocin-
induced DR through maintaining synapse integrity in the vertical pathway [ 94 ]. 
 D’Amico and coworkers [ 95 ] analyzed the expression of hypoxia-induced fac-
tors (HIF) in DR 3 weeks after the induction of diabetes with streptozotocin. They 
found that the expression of HIF-1α and HIF-2α signiﬁ cantly increased in diabetic 
rats, but not after 1 intravitreal PACAP treatment. Conversely, the expression of 
HIF-3α was signiﬁ cantly downregulated in retinas of diabetic rats, and increased 
after PACAP treatment. These results suggest that the retinoprotective effects of 
PACAP are partially mediated by interfering with the expression of HIFs that play 
an important role in pathological vasculogenesis occurring in DR [ 95 ]. 
 These studies, together with the results demonstrating the effects of PACAP on 
the blood–retinal barrier properties in vitro (see above), show that PACAP has ther-
apeutic potential in DR [ 96 – 98 ]. Several experiments support the efﬁ cacy of PACAP 
treatment in animal models of diabetes-related diseases, such as DR, another major 
microangiopathic complication of diabetes [ 99 ,  100 ]. Thus, PACAP is among the 
emerging molecules to ﬁ ght diabetic complications, similarly to VEGF antagonists, 
antioxidants, anti- inﬂ ammatory agents, and other neuropeptides [ 96 ,  101 ,  102 ]. 
 Retinopathy of Prematurity (ROP) 
 ROP is a major complication in premature newborns. It is a vasoproliferative disorder, 
the main features of which are well depicted in a rat model of oxygen-induced reti-
nopathy. Our preliminary studies have shown that PACAP is able to reverse some of 
the deleterious effects of this retinopathy. Intravitreal PACAP1-38 treatment amelio-
rated the vascular extent of the retinopathic eyes without alterations in vessel morphol-
ogy. Moreover, cytokine expression proﬁ les indicate that PACAP may block the new 
vessel formation and have a positive inﬂ uence on the remodeling of the tissue [ 103 ]. 
 Studies in PACAP and Receptor Gene Modifi ed Animals 
 We have described that although PACAP deﬁ cient mice have normal retinas at 
young age, aging signs appear earlier than in their wild-type mates [ 104 ]. As it has 
been shown in numerous models, PACAP knockout (KO) mice are more 
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vulnerable to different types of tissue injuries from ischemia to oxidative stress 
and even trauma [ 105 ]. In our experiments, PACAP KO mice that underwent 
10 min of BCCAO followed by 2-week reperfusion period had signiﬁ cantly greater 
retinal damage, as shown by the thickness of the whole retina, the morphometric 
analysis of the individual retinal layers, and the cell numbers in the INL and GCL. 
Exogenous PACAP administration could partially protect against this retinal 
degeneration in the KO mice. These results clearly show that endogenous PACAP 
reacts as a stress-response peptide that is necessary for endogenous protection 
against different retinal insults [ 106 ]. 
 The higher vulnerability of PACAP deﬁ cient mice against lesions was conﬁ rmed 
by another study by Endo et al. [ 107 ]. The authors found, in accordance with our 
results, that under normal circumstances, there was no difference in the number of 
retinal ganglion cells in heterozygous PACAP deﬁ cient mice and wild-type counter-
parts [ 107 ]. However, when these mice were subjected to NMDA-induced toxicity, 
PACAP heterozygous mice reacted with increased loss of ganglion cells [ 107 ]. The 
number of apoptotic cells, as measured by TUNEL staining, peaked on day 1 in 
heterozygous mice, while the peak was on day 3 in wild types, suggesting that apop-
totic cell death began earlier in mice deﬁ cient in PACAP. These effects were reversed 
by simultaneous injection of PACAP in heterozygous mice. These results conﬁ rm 
that endogenous PACAP is protective in the retina and prove that even partial loss 
of PACAP-driven neuroprotection decreases resistance against harmful effects 
[ 107 ]. Our recent, preliminary results also conﬁ rm that endogenous PACAP is pro-
tective in lipopolysaccharide (LPS)-induced retinal inﬂ ammation, as shown by the 
increased inﬂ ammatory status of PACAP KO. Twenty-four hours after LPS treat-
ment several cytokines and chemokines showed signiﬁ cant increase in the PACAP 
knockout mice compared to the normal, wild types [ 108 ]. 
 Little is known about retinal morphology or function in mice with PAC1 receptor 
abnormalities. Engelund and coworkers [ 109 ] described that pupillary light reﬂ ex 
was altered in PAC1 receptor knockout mice. The ﬁ nding that PACAPergic signal-
ing is essential for normal retinal development is also conﬁ rmed by studies with 
transgenic mice. It was described by Lang et al. [ 110 ] during development that over-
expression of the PAC1 receptor led to an early exit from retinal proliferation, 
reduced signaling of GABAergic neurons. Furthermore, this led to decreased visual 
function [ 110 ]. These data show that a proper balance of PACAP signaling is 
required for appropriate retinogenesis and visual acuity. 
 Studies in Tumor Cells 
 PACAP can exert different effects in cells derived from various sources and espe-
cially from tumors. While in most cell types PACAP is protective, in some tumors 
it exerts toxic effects [ 111 ]. Furthermore, PACAP6-38 is in most cell types an antag-
onist, it can also behave as an agonist in some, tumorous and even non-tumorous, 
cells [ 112 ,  113 ]. Retinoblastoma is a malignant tumor of retinal progenitor cells. 
Human retinoblastoma cells are known to express PACAP receptors [ 114 ]. In Y79 
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retinoblastoma cells, PACAP1-38 did not inﬂ uence cell survival at nanomolar con-
centrations, but at 1–5 μM concentrations, it reduced survival [ 115 ]. Interestingly, 
PACAP1-27 and maxadilan had negligible effects, while two membrane- penetrating 
analogs of PACAP also decreased cell viability. The authors also revealed that this 
cytotoxic effect might be via an interaction of p38, MEK1/2, and JNK signaling, 
because inhibitors of these pathways led to an even more expressed cytotoxicity 
[ 115 ]. These results suggest that high concentrations of PACAP1-38 might lead to a 
transmembrane penetration and lead to direct cytotoxicity at sites other than the 
conventional PACAP receptor-mediated signaling. 
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